GGrantIndex
← Leaderboards

Crystal A. Gadegbeku

Medical University Of South Carolina

$5,788,715
Attributed
$8,128,714
Total exposure
14
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,128,714 · 14

By mechanism

U24$3,509,999 · 1
P30$2,101,615 · 1
R33$1,720,805 · 1
K23$623,749 · 1
M01$172,546 · 10

Top collaborators

Most similar at Medical University Of South Carolina

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHypertensionFundingKidney DiseasesResearch PersonnelHuman SubjectInsulin Sensitivity /ResistancePathogenesisDisease /Disorder Proneness /RiskBlood PressureInsulinFatty Acid MetabolismProgramsAdrenergic ReceptorPhenylephrineFollow-UpParticipantAffectCohortGlomerular Filtration RateCareerBloodHigh RiskLink

Grant awards (37)

CureGN$1,400,000
U24 · FY2025 · DK
CureGN$224,000
U24 · FY2025 · DK
CureGN$1,399,999
U24 · FY2024 · DK
CureGN$486,000
U24 · FY2024 · DK
Clinical Phenotyping Resource and Biobank Core (C-PROBE)$406,448
P30 · FY2017 · DK · contact PI
Clinical Phenotyping Resource and Biobank Core (C-PROBE)$406,448
P30 · FY2016 · DK · contact PI
Clinical Phenotyping Resource and Biobank Core (C-PROBE)$406,448
P30 · FY2015 · DK · contact PI
Clinical Phenotyping Resource and Biobank Core (C-PROBE)$406,448
P30 · FY2014 · DK · contact PI
Clinical Phenotyping Resource and Biobank Core (C-PROBE)$475,823
P30 · FY2013 · DK · contact PI
Mechanisms of Hypertension in Chronic Kidney Disease$325,939
R33 · FY2009 · DK · contact PI
Mechanisms of Hypertension in Chronic Kidney Disease$350,119
R33 · FY2008 · DK · contact PI
Mechanisms of Hypertension in Chronic Kidney Disease$348,589
R33 · FY2007 · DK · contact PI
RETINOPATHY IN CHRONIC RENAL INSUFFICIENCY (RCRIC)$53,552
M01 · FY2007 · RR · contact PI
PULSE WAVE ANALYSIS IN CRIC$23,501
M01 · FY2007 · RR · contact PI
PILOT STUDY ON THE ROLE OF NITRIC OXIDE IN A1 ADRENERGIC VASOREACTIVITY$9,265
M01 · FY2007 · RR · contact PI
ALPHA-ADRENOCEPTOR VASCULAR FUNCTION IN CHRONIC KIDNEY DISEASE$4,294
M01 · FY2007 · RR · contact PI
Mechanisms of Hypertension in Chronic Kidney Disease$349,052
R33 · FY2006 · DK · contact PI
PILOT STUDY ON THE ROLE OF NITRIC OXIDE IN A1 ADRENERGIC VASOREACTIVITY$32,191
M01 · FY2006 · RR · contact PI
PULSE WAVE VELOCITY IN CRIC$19,417
M01 · FY2006 · RR · contact PI
INCREASED ALPHA1-ADRENOCEPTOR-MEDIATED PRESSOR SENSITIVITY & CHRONIC RENAL DIS$1,533
M01 · FY2006 · RR · contact PI
Mechanisms of Hypertension in Chronic Kidney Disease$347,106
R33 · FY2005 · DK
INCREASED ALPHA1-ADRENOCEPTOR-MEDIATED PRESSOR SENSITIVITY &CHRONIC RENAL DIS$15,439
M01 · FY2005 · RR
MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$125,134
K23 · FY2004 · RR
Increased Alpha1-adrenoceptor-mediated Pressor Sensitivity &Chronic Renal Dis.$8,132
M01 · FY2004 · RR
Mechanisms underlying increased Alpha-Adrenoceptor-Mediated Pressor Sensitivi...$5,222
M01 · FY2004 · RR
MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$113,200
K23 · FY2003 · RR
MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$11,934
K23 · FY2003 · RR
MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$125,134
K23 · FY2002 · RR
EFFECTS OF FATTY ACIDS IN CHRONIC RENAL INSUFFICIENCY$0
M01 · FY2002 · RR
FATTY ACIDS ON VASCULAR REACTIVITY IN RENAL FAILURE$0
M01 · FY2002 · RR
MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$125,134
K23 · FY2001 · RR
EFFECTS OF FATTY ACIDS IN CHRONIC RENAL INSUFFICIENCY$0
M01 · FY2001 · RR
EFFECTS OF FATTY ACIDS IN CHRONIC RENAL INSUFFICIENCY$0
M01 · FY2001 · RR
EFFECTS OF FATTY ACIDS IN CHRONIC RENAL INSUFFICIENCY$0
M01 · FY2001 · RR
MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$123,213
K23 · FY2000 · RR
EFFECTS OF FATTY ACIDS IN CHRONIC RENAL INSUFFICIENCY$0
M01 · FY2000 · RR
FATTY ACIDS ON VASCULAR REACTIVITY IN RENAL FAILURE$0
M01 · FY2000 · RR